Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury

Next Previous
Trial Profile

Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 Oct 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sertraline (Primary)
  • Indications Affective disorders; Anxiety disorders
  • Focus Therapeutic Use

Most Recent Events

  • 14 Sep 2016 Primary endpoint (Time to Onset of Diagnostic and Statistical Manual (DSM) IV Defined Mood and Anxiety Disorders Associated With Traumatic Brain Injury (TBI)), has been met, accoding to Results published in the JAMA Psychiatry.
  • 14 Sep 2016 Results published in the JAMA Psychiatry
  • 20 Jan 2010 Planned number of patients changed from 45 to 104 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top